COMPARED WITH PATIENTS in Croatian translation

by Month 12 compared with patients receiving placebo in combination with allopurinol see Table 2.

do dvanaestog mjeseca u usporedbi s bolesnicima u kojih je primijenjen placebo u kombinaciji s alopurinolom vidjeti Tablicu 2.

Autologous Stem Cell Transplant(ASCT) compared with patients who received placebo 1.27 to 1.56 versus 0.46 to 0.53 per 100 person-years.

visoke doze melfalana i transplantacije autolognih matičnih stanica u usporedbi s bolesnicima koji su primali placebo 1, 27 do 1, 56 naspram 0, 46 do 0, 53 na 100 osoba-godina.

MTX(p< 0.0001) compared with patients who were randomised to placebo plus MTX.

0,0001) u usporedbi s bolesnicima koji su randomizirani u skupinu koja je primala placebo i MTX.

maximum elimination rate of paclitaxel and approximately 20% increase in mean paclitaxel AUC compared with patients with normal hepatic function.

a povećanje srednje vrijednosti AUC-a paklitaksela iznosi približno 20% u usporedbi s bolesnicima s normalnom jetrenom funkcijom.

The decline in distance walked during a 6MWT from Baseline to Week 52 was significantly reduced in patients receiving Esbriet compared with patients receiving placebo in PIPF-016(p=0.036, rank ANCOVA);

U ispitivanju PIPF-016, smanjenje udaljenosti prijeđene tijekom 6MWT testa od početnih vrijednosti do onih izmjerenih u 52. tjednu bilo je značajno manje u bolesnika koji su primali Esbriet u usporedbi s bolesnicima koji su primali placebo(p=0,

Patients receiving Cimzia and concomitant methotrexate had a lower humoral response compared with patients receiving Cimzia alone.

Bolesnici koji su istodobno primali Cimziju i metotreksat imali su smanjeni humoralni odgovor u usporedbi s bolesnicima koji su primali samo Cimziju.

Statistically significant improvements in HAQ-DI scores were observed in patients treated with RoActemra compared with patients treated with DMARDs.

Kod bolesnika liječenih lijekom RoActemra u usporedbi s bolesnicima liječenima DMARD lijekovima opaženo je statistički značajno poboljšanje HAQ-DI rezultata.

efficacy were observed in patients under the age of 2 years compared with patients aged 2 years and above.

razlike u sigurnosti ili djelotvornosti u bolesnika mlađih od 2 godine u usporedbi s bolesnicima u dobi od 2 i više godina.

During a randomised withdrawal period, significantly more patients re-randomised to placebo experienced disease relapse(loss of PASI 75 response) compared with patients re-randomised to Enbrel.

Tijekom randomiziranog razdoblja prekida terapije, znatno više bolesnika koji su ponovno randomizirani u skupinu s placebom ušlo je u recidiv bolesti(gubitak odgovora PASI 75) u usporedbi s bolesnicima koji su ponovno randomizirani u skupinu s Enbrelom.

Patients who received Afinitor and best supportive treatments were compared with patients who received placebo(a dummy treatment)

Bolesnici koji su primali lijek Afinitor i najbolje dodatno liječenje uspoređeni su s bolesnicima koji su primali placebo(slijepo liječenje)

Lenalidomide treatment in mantle cell lymphoma patients is associated with a higher incidence of grade 3 and 4 neutropenia compared with patients on the control arm see section 4.8.

Liječenje lenalidomidom u bolesnika s limfomom plaštenih stanica povezano je s višom incidencijom neutropenije 3. i 4. stupnja u usporedbi s bolesnicima kontrolne skupine vidjeti dio 4.8.

patients treated with alirocumab who developed ADA had a lower incidence of injection site reactions compared with patients who did not develop ADA 8.6% vs 16.2.

koji su razvili protutijela na lijek, imali manju incidenciju reakcija na mjestu injiciranja u usporedbi s bolesnicima koji nisu razvili protutijela na lijek 8,6% naspram 16, 2.

0.001) compared with patients randomised to placebo.

0,001) u usporedbi s bolesnicima koji su primali placebo.

Patients with mild and moderate renal impairment had at steady state an average 1.8-fold and 3.6-fold higher pre-dose dabigatran plasma concentrations compared with patients with CrCL> 80 mL/min, respectively.

Bolesnici s blagim i umjerenim oštećenjem bubrega imali su, pri stanju ravnoteže, prosječno 1, 8 puta odnosno 3, 6 puta više koncentracije dabigatrana u plazmi prije doziranja, u usporedbi s bolesnicima s CrCL> 80 mL/min.

5 more with non-CABG-related TIMI major haemorrhages, compared with patients treated with clopidogrel.

se broj onih sa značajnim krvarenjem(prema TIMI) nevezanim uz CABG povećao za 5 u usporedbi s bolesnicima liječenima klopidogrelom.

Patients treated with Perjeta, trastuzumab and docetaxel are at increased risk of febrile neutropenia compared with patients treated with placebo,

Bolesnici liječeni lijekom Perjeta, trastuzumabom i docetakselom izloženi su povećanom riziku od febrilne neutropenije u usporedbi s bolesnicima koji primaju placebo,

A single-dose, open-label study was conducted to evaluate the pharmacokinetics of 60 mg lomitapide in healthy volunteers with normal hepatic function compared with patients with mild(Child-Pugh A) and moderate(Child-Pugh B) hepatic impairment.

Otvoreno ispitivanje s jednostrukom dozom provedeno je kako bi se procijenila farmakokinetika doze lomitapida od 60 mg u zdravih dobrovoljaca s normalnom funkcijom jetre, u usporedbi s bolesnicima s blagim(Child-Pugh A) i umjerenim(Child-Pugh B) oštećenjem funkcije jetre.

A greater percentage of patients treated with vehicle experienced a decrease in BCVA of more than 5 letters from day 7 to day 90(or early exit)(11.5%) compared with patients treated with nepafenac 5.6.

Veći postotak bolesnika liječenih podlogom lijeka doživio je smanjenje u vrijednosti u najbolje korigiranoj oštrini vida(BCVA, engl. best corrected vision accurity) za više od 5 slova u danima od 7 do 90(ili ranijeg izlaza)(11,5%) u usporedbi s bolesnicima liječenim s Nepafenakom 5, 6.

CKD 5D patients treated with Fexeric, compared with patients treated with active control,

bolesnici s KBB 5D liječeni Fexericom imali su, u usporedbi s bolesnicima liječenim aktivnom kontrolom,

An increased incidence of febrile neutropenia was observed among Asian patients in both treatment groups compared with patients of other races

U obje je terapijske skupine primijećena povećana incidencija febrilne neutropenije u bolesnika azijskog podrijetla u usporedbi s bolesnicima drugih rasa